i n f l a r x

Loading

Impressum Privacy policy

Contact us

+49 3641 508 180

info@inflarx.de

Address

InflaRx N.V.

Winzerlaer Str. 2, 07745 Jena

Development Pipeline
Home R & D Pipeline

Pipeline

INFLAMMATION & IMMUNOLOGY (I&I)
Program
Preclinical
Phase 1
Phase 2
Phase 3
Market
Status & Milestones
hidradenitis suppurativa

Topline Phase 2a reported with Ph2b planning ongoing

chronic spontaneous urticaria

Topline Phase 2a reported

other immuno-dermatology

Additional indications in immuno-dermatology

broader I&I

Additional chronic indications including nephrology, hematology, neurology and others

CRITICAL CARE
Program
Preclinical
Phase 1
Phase 2
Phase 3
Market
Status & Milestones
critical COVID-19

US EUA granted*

SARS-CoV-2-induced ARDS

Approved by European Commission*

Broader ARDS

Phase 2 "Just Breathe" ASPR/BARDA clinical platform study

DERMATOLOGY
Program
Preclinical
Phase 1
Phase 2
Phase 3
Market
Status & Milestones
pyoderma gangrenosum

Phase 3 reported**

OTHER
Program
Preclinical
Phase 1
Phase 2
Phase 3
Market
Status & Milestones
Vilobelimab Life-cycle approach

For optimized use in chronic inflammatory indications

*Commercial partnering and distribution options in the EU being considered.
** Phase 3 stopped early for futility at interim analysis, FDA interaction considered.

See also in R&D: